Evidence map›Paper›PMID 31237611›Full record

ArticleEndocrinology2019

1,25-Dihydroxyvitamin D Maintains Brush Border Membrane NaPi2a and Attenuates Phosphaturia in Hyp Mice.

Janaina S Martins, Eva S Liu, W Bruce Sneddon, Peter A Friedman, Marie B Demay

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Approach to Hypophosphatemic Rickets.The Journal of clinical endocrinology and metabolism · 2022
    Article
  4. Article
  5. Review
  6. Effects of Active Vitamin D or FGF23 Antibody onJournal of dental research · 2021
    Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Janaina S MartinsEndocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
Eva S LiuEndocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
W Bruce SneddonLaboratory for GPCR Biology, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Peter A FriedmanLaboratory for GPCR Biology, Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Marie B DemayEndocrine Unit, Massachusetts General Hospital, Boston, Massachusetts.
Harvard University · USUniversity of Pittsburgh · USBrigham and Women's Hospital · US

Funding

Hormonal Regulation of NHERF1 in BoneR01DK105811 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRIEDMAN, PETER A · 2016 to 2019
$2.5M
Functional Polarity of PTH Receptor Signaling: Cellular and Molecular MechanismsR01DK111427 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRIEDMAN, PETER A, VILARDAGA, JEAN-PIERRE · 2017 to 2020
$2.4M
Hormonal and Molecular Etiology of Skeletal Abnormalities in XLHR01AR072650 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI DEMAY, MARIE · 2017 to 2021
$1.8M
Molecular and cellular determinants of enthesopathy in X-linked hypophosphatemiaK08AR067854 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI LIU, EVA S. · 2015 to 2019
$699k
NIAMS NIH HHS K08 AR067854NIAMS NIH HHS R01 AR072650NIDDK NIH HHS R01 DK105811NIDDK NIH HHS R01 DK111427
6 · The paper itself

Abstract

Phosphate homeostasis is critical for many cellular processes and is tightly regulated. The sodium-dependent phosphate cotransporter, NaPi2a, is the major regulator of urinary phosphate reabsorption in the renal proximal tubule. Its activity is dependent upon its brush border localization that is regulated by fibroblast growth factor 23 (FGF23) and PTH. High levels of FGF23, as are seen in the Hyp mouse model of human X-linked hypophosphatemia, lead to renal phosphate wasting. Long-term treatment of Hyp mice with 1,25-dihydroxyvitamin D (1,25D) or 1,25D analogues has been shown to improve renal phosphate wasting in the setting of increased FGF23 mRNA expression. Studies were undertaken to define the cellular and molecular basis for this apparent FGF23 resistance. 1,25D increased FGF23 protein levels in the cortical bone and circulation of Hyp mice but did not impair FGF23 cleavage. 1,25D attenuated urinary phosphate wasting as early as one hour postadministration, without suppressing FGF23 receptor/coreceptor expression. Although 1,25D treatment induced expression of early growth response 1, an early FGF23 responsive gene required for its phosphaturic effects, it paradoxically enhanced renal phosphate reabsorption and NaPi2a protein expression in renal brush border membranes (BBMs) within one hour. The Na-H+ exchange regulatory factor 1 (NHERF1) is a scaffolding protein thought to anchor NaPi2a to the BBM. Although 1,25D did not alter NHERF1 protein levels acutely, it enhanced NHERF1-NaPi2a interactions in Hyp mice. 1,25D also prevented the decrease in NHERF1/NaPi2a interactions in PTH-treated wild-type mice. Thus, these investigations identify a novel role for 1,25D in the hormonal regulation of renal phosphate handling.

Indexed as

AnimalsCell LineEpithelial CellsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGene Expression RegulationHypophosphatemiaHypophosphatemia, FamilialKidney Tubules, ProximalMaleMAP Kinase Signaling SystemMiceProtein TransportReceptors, Fibroblast Growth FactorSodium-Phosphate Cotransporter Proteins, Type IIa1,25-dihydroxyvitamin DFGF23 protein, humanFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsReceptors, Fibroblast Growth FactorSodium-Phosphate Cotransporter Proteins, Type IIaVitamin D

Identifiers

PMID31237611
PMCPMC6735734
OpenAlexW2953888286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.